Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

Table 1 Baseline demographics

	Ubrogepant + OnabotulinumtoxinA^a n = 122
Age, mean (SD), years	40.4 (10.3)
Female, n (%)	117 (95.9)
Race, White, n (%)	107 (92.2)^b
PHQ-4,^c mean (SD)	7.8 (3.0)
MIDAS grade, n (%)
I (minimal)	3 (2.5)
II (mild)	3 (2.5)
III (moderate)	10 (8.2)
IVa (severe)	20 (16.4)
IVb (very severe)	86 (70.5)
Ubrogepant, n (%)
50 mg	54 (44.3)
100 mg	68 (55.7)

Abbreviations: MIDAS Migraine Disability Assessment, PHQ-4 Patient Health Questionnaire-4, SD standard deviation
^aExcluding 2 missing responses, all participants reported that they received onabotulinumtoxinA injections in the forehead, side and back of head, and neck
^bPercentage is out of the number of participants with available race data (n=116)
^cPHQ-4 scale ranges from 0–12 with total scores as follows: normal (0–2), mild (3–5), moderate (6–8), severe (9–12)

ISSN: 1129-2377